Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
Alicia Okines(Royal Marsden NHS Foundation Trust), David Cunningham(Royal Marsden NHS Foundation Trust), Stephen Falk(At Bristol), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Daniel Ford(Queen Elizabeth Hospital Birmingham), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Justin S. Waters(Maidstone Hospital), Sally Stenning(Medical Research Council), Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), S M Griffin(Unknown), Lindsay C Thompson(Medical Research Council), Chris Plummer(Newcastle upon Tyne Hospitals NHS Foundation Trust), Russell Petty(Aberdeen Royal Infirmary), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Michel Seymour(University of Leeds), Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Leanne Stevenson(Queen's University Belfast), David B. Smith(Wirral University Teaching Hospital NHS Foundation Trust), S. Slater(St Bartholomew's Hospital), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Linda Evans(Weston Park Cancer Centre), William Allum(Royal Marsden Hospital)
Cited by 67
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k